. "\u30D3\u30AA\u30E1\u30EA\u30E5\u30FC\uFF08\u4ECF: bioM\u00E9rieux S.A.\uFF09\u306F\u3001\u5FAE\u751F\u7269\u691C\u67FB\u3001\u907A\u4F1D\u5B50\u691C\u67FB\u3001\u514D\u75AB\u691C\u67FB\u306A\u3069\u3001\u4F53\u5916\u8A3A\u65AD\u7528\u306E\u533B\u85AC\u54C1\u304A\u3088\u3073\u533B\u7642\u6A5F\u5668\u306E\u958B\u767A\u30FB\u8CA9\u58F2\u3092\u884C\u3046\u4F01\u696D\u3002\u30D5\u30E9\u30F3\u30B9\u30FB\u30E1\u30C8\u30ED\u30DD\u30FC\u30EB\u30FB\u30C9\u30FB\u30EA\u30E8\u30F3\u306E\u30DE\u30EB\u30B7\u30FC\uFF1D\u30EC\u30C8\u30EF\u30FC\u30EB\u306B\u672C\u62E0\u3092\u7F6E\u304D\u3001\u4E16\u754C160\u304B\u56FD\u4EE5\u4E0A\u3067\u88FD\u54C1\u3092\u8CA9\u58F2\u3059\u308B\u3002\u30E6\u30FC\u30ED\u30CD\u30AF\u30B9\u30C8\u30FB\u30D1\u30EA\u4E0A\u5834\u4F01\u696D\uFF08Euronext: BIM \uFF09\u3002"@ja . . . . "CAC Next 20 component"@en . "bioM\u00E9rieux (Euronext: BIM) es una empresa francesa especializada en diagn\u00F3stico in vitro. Fundada en 1963, se encuentra en Marcy-l'\u00C9toile, cerca de Lyon. Presente en m\u00E1s de 160 pa\u00EDses a trav\u00E9s de 44 emplazamientos, su facturaci\u00F3n en 2020 ascendi\u00F3 a 3.100 millones de euros, m\u00E1s del 93% de los cuales se gener\u00F3 a nivel internacional.\u200B La empresa ofrece servicios de diagn\u00F3stico (sistemas, reactivos, software, servicios) que determinan el origen de una enfermedad o contaminaci\u00F3n. Sus productos se utilizan principalmente en el diagn\u00F3stico de enfermedades infecciosas. Tambi\u00E9n se utilizan para la detecci\u00F3n de microorganismos en productos alimenticios, farmac\u00E9uticos y cosm\u00E9ticos.\u200B"@es . . "12800"^^ . "bioM\u00E9rieux ist ein b\u00F6rsennotiertes franz\u00F6sisches Unternehmen. Es stellt Reagenzien, Ger\u00E4te, Software und Service f\u00FCr die In-vitro-Diagnostik her. bioM\u00E9rieux geh\u00F6rt mehrheitlich dem 1987 gegr\u00FCndeten ."@de . . . "BioM\u00E9rieux"@pt . . "Dr Charles M\u00E9rieux"@en . . . "BioM\u00E9rieux"@en . . "BioM\u00E9rieux"@it . . "Biomerieux"@es . . . . "BioM\u00E9rieux est une entreprise fran\u00E7aise sp\u00E9cialis\u00E9e dans le diagnostic in vitro. Fond\u00E9e en 1963, elle est situ\u00E9e \u00E0 Marcy-l'\u00C9toile pr\u00E8s de Lyon. Pr\u00E9sente dans plus de 160 pays au travers de 44 sites, son chiffre d'affaires en 2020 s\u2019\u00E9l\u00E8ve \u00E0 3,1 milliards d'euros, dont plus de 93 % r\u00E9alis\u00E9s \u00E0 l\u2019\u00E9tranger."@fr . . . . "1963"^^ . . "bioM\u00E9rieux (fondata come BD M\u00E9rieux) \u00E8 un'azienda francese operante nel settore medicale \u2013 microbiologia e diagnostica \u2013, e specialista mondiale della diagnostica in vitro. Nel 1897, \u2013 ex allievo di Louis Pasteur \u2013 fond\u00F2 a Lione l', un laboratorio per realizzare dei vaccini antitetanici. La bioM\u00E9rieux \u00E8 presente in pi\u00F9 di 160 paesi nel mondo, attraverso 43 filiali, 18 siti industriali e 17 centri di ricerca."@it . . . . . . . "\uBE44\uC624\uBA54\uB9AC\uC720(\uD504\uB791\uC2A4\uC5B4: bioM\u00E9rieux, \uC720\uB85C\uB125\uC2A4\uD2B8: BIM)\uB294 \uD504\uB791\uC2A4\uC5D0\uC11C \uC124\uB9BD\uB418\uC5B4 \uBCF8\uC0AC\uB97C \uB454 \uB2E4\uAD6D\uC801 \uC0DD\uBA85\uACF5\uD559 \uC9C4\uB2E8\uD68C\uC0AC\uC774\uB2E4. \uBE44\uC624\uBA54\uB9AC\uC720\uB294 42\uAC1C\uC758 \uC790\uD68C\uC0AC\uC640 \uB300\uADDC\uBAA8 \uC720\uD1B5 \uC5C5\uCCB4 \uB124\uD2B8\uC6CC\uD06C\uB97C \uD1B5\uD574 150\uC5EC\uAD6D\uC5D0\uC11C \uC601\uC5C5\uC744 \uD558\uACE0\uC788\uB2E4. \uBE44\uC624\uBA54\uB9AC\uC720\uB294 \uD658\uC790\uC758 \uAC74\uAC15\uC744 \uAC1C\uC120\uD558\uACE0 \uC18C\uBE44\uC790 \uC548\uC804\uC744 \uBCF4\uC7A5\uD558\uAE30 \uC704\uD574 \uC9C8\uBCD1 \uBC0F \uC624\uC5FC\uC6D0\uC744 \uACB0\uC815\uD558\uB294 \uC9C4\uB2E8 \uC194\uB8E8\uC158 (\uC2DC\uC57D, \uAE30\uAE30, \uC18C\uD504\uD2B8\uC6E8\uC5B4)\uC744 \uC81C\uACF5\uD55C\uB2E4. \uC774 \uC81C\uD488\uC740 \uC804\uC5FC\uBCD1 \uC9C4\uB2E8, \uC554 \uAC80\uC9C4 \uBC0F \uBAA8\uB2C8\uD130\uB9C1, \uADF8\uB9AC\uACE0 \uC751\uAE09 \uC0C1\uD669\uC5D0\uC11C\uC758 \uC2EC\uD608\uAD00 \uC9C4\uB2E8\uC5D0 \uC0AC\uC6A9\uB41C\uB2E4. \uB610\uD55C \uB18D\uC2DD\uD488, \uC758\uC57D\uD488 \uBC0F \uD654\uC7A5\uD488\uC5D0\uC11C \uBBF8\uC0DD\uBB3C\uC744 \uD0D0\uC9C0\uD558\uB294 \uB370 \uC0AC\uC6A9\uB41C\uB2E4. \uBE44\uC624\uBA54\uB9AC\uC720\uB294 NYSE Euronext Paris \uC99D\uAD8C \uAC70\uB798\uC18C (BIM \u2013 ISIN : FR0010096479)\uC5D0 \uC0C1\uC7A5\uB418\uC5B4 \uC788\uB2E4."@ko . . "\u751F\u7269\u6885\u91CC\u57C3\uFF08\u6CD5\u8A9E\uFF1AbioM\u00E9rieux\uFF09\u662F\u4E00\u5BB6\u6CD5\u570B\u7684\u751F\u7269\u6280\u672F\u8DE8\u570B\u516C\u53F8\uFF0C\u8A72\u516C\u53F8\u5171\u670942\u4E2A\u5B50\u516C\u53F8\uFF0C\u696D\u52D9\u904D\u53CA\u5168\u7403150\u591A\u4E2A\u56FD\u5BB6\u548C\u5730\u3002"@zh . "\uBE44\uC624\uBA54\uB9AC\uC720"@ko . "\uBE44\uC624\uBA54\uB9AC\uC720(\uD504\uB791\uC2A4\uC5B4: bioM\u00E9rieux, \uC720\uB85C\uB125\uC2A4\uD2B8: BIM)\uB294 \uD504\uB791\uC2A4\uC5D0\uC11C \uC124\uB9BD\uB418\uC5B4 \uBCF8\uC0AC\uB97C \uB454 \uB2E4\uAD6D\uC801 \uC0DD\uBA85\uACF5\uD559 \uC9C4\uB2E8\uD68C\uC0AC\uC774\uB2E4. \uBE44\uC624\uBA54\uB9AC\uC720\uB294 42\uAC1C\uC758 \uC790\uD68C\uC0AC\uC640 \uB300\uADDC\uBAA8 \uC720\uD1B5 \uC5C5\uCCB4 \uB124\uD2B8\uC6CC\uD06C\uB97C \uD1B5\uD574 150\uC5EC\uAD6D\uC5D0\uC11C \uC601\uC5C5\uC744 \uD558\uACE0\uC788\uB2E4. \uBE44\uC624\uBA54\uB9AC\uC720\uB294 \uD658\uC790\uC758 \uAC74\uAC15\uC744 \uAC1C\uC120\uD558\uACE0 \uC18C\uBE44\uC790 \uC548\uC804\uC744 \uBCF4\uC7A5\uD558\uAE30 \uC704\uD574 \uC9C8\uBCD1 \uBC0F \uC624\uC5FC\uC6D0\uC744 \uACB0\uC815\uD558\uB294 \uC9C4\uB2E8 \uC194\uB8E8\uC158 (\uC2DC\uC57D, \uAE30\uAE30, \uC18C\uD504\uD2B8\uC6E8\uC5B4)\uC744 \uC81C\uACF5\uD55C\uB2E4. \uC774 \uC81C\uD488\uC740 \uC804\uC5FC\uBCD1 \uC9C4\uB2E8, \uC554 \uAC80\uC9C4 \uBC0F \uBAA8\uB2C8\uD130\uB9C1, \uADF8\uB9AC\uACE0 \uC751\uAE09 \uC0C1\uD669\uC5D0\uC11C\uC758 \uC2EC\uD608\uAD00 \uC9C4\uB2E8\uC5D0 \uC0AC\uC6A9\uB41C\uB2E4. \uB610\uD55C \uB18D\uC2DD\uD488, \uC758\uC57D\uD488 \uBC0F \uD654\uC7A5\uD488\uC5D0\uC11C \uBBF8\uC0DD\uBB3C\uC744 \uD0D0\uC9C0\uD558\uB294 \uB370 \uC0AC\uC6A9\uB41C\uB2E4. \uBE44\uC624\uBA54\uB9AC\uC720\uB294 NYSE Euronext Paris \uC99D\uAD8C \uAC70\uB798\uC18C (BIM \u2013 ISIN : FR0010096479)\uC5D0 \uC0C1\uC7A5\uB418\uC5B4 \uC788\uB2E4."@ko . . . . "Euronext:BIM"@en . "BioM\u00E9rieux"@fr . "BioM\u00E9rieux est une entreprise fran\u00E7aise sp\u00E9cialis\u00E9e dans le diagnostic in vitro. Fond\u00E9e en 1963, elle est situ\u00E9e \u00E0 Marcy-l'\u00C9toile pr\u00E8s de Lyon. Pr\u00E9sente dans plus de 160 pays au travers de 44 sites, son chiffre d'affaires en 2020 s\u2019\u00E9l\u00E8ve \u00E0 3,1 milliards d'euros, dont plus de 93 % r\u00E9alis\u00E9s \u00E0 l\u2019\u00E9tranger. L'entreprise offre des prestations de diagnostic (syst\u00E8mes, r\u00E9actifs, logiciels, services) qui d\u00E9terminent l\u2019origine d\u2019une maladie ou d\u2019une contamination. Ses produits sont utilis\u00E9s principalement dans le diagnostic des maladies infectieuses. Ils sont \u00E9galement utilis\u00E9s pour la d\u00E9tection de micro-organismes dans les produits agroalimentaires, pharmaceutiques et cosm\u00E9tiques."@fr . . . "\u30D3\u30AA\u30E1\u30EA\u30E5\u30FC\uFF08\u4ECF: bioM\u00E9rieux S.A.\uFF09\u306F\u3001\u5FAE\u751F\u7269\u691C\u67FB\u3001\u907A\u4F1D\u5B50\u691C\u67FB\u3001\u514D\u75AB\u691C\u67FB\u306A\u3069\u3001\u4F53\u5916\u8A3A\u65AD\u7528\u306E\u533B\u85AC\u54C1\u304A\u3088\u3073\u533B\u7642\u6A5F\u5668\u306E\u958B\u767A\u30FB\u8CA9\u58F2\u3092\u884C\u3046\u4F01\u696D\u3002\u30D5\u30E9\u30F3\u30B9\u30FB\u30E1\u30C8\u30ED\u30DD\u30FC\u30EB\u30FB\u30C9\u30FB\u30EA\u30E8\u30F3\u306E\u30DE\u30EB\u30B7\u30FC\uFF1D\u30EC\u30C8\u30EF\u30FC\u30EB\u306B\u672C\u62E0\u3092\u7F6E\u304D\u3001\u4E16\u754C160\u304B\u56FD\u4EE5\u4E0A\u3067\u88FD\u54C1\u3092\u8CA9\u58F2\u3059\u308B\u3002\u30E6\u30FC\u30ED\u30CD\u30AF\u30B9\u30C8\u30FB\u30D1\u30EA\u4E0A\u5834\u4F01\u696D\uFF08Euronext: BIM \uFF09\u3002"@ja . "bioM\u00E9rieux \u00E9 uma empresa francesa especializada em diagn\u00F3sticos in vitro. Fundado em 1963, est\u00E1 localizado em , pr\u00F3ximo a Lyon. Presente em mais de 160 pa\u00EDses atrav\u00E9s de 44 localidades, o seu volume de neg\u00F3cios em 2020 ascendeu a 3.100 milh\u00F5es de euros, dos quais mais de 93% foram gerados a n\u00EDvel internacional."@pt . "bioM\u00E9rieux (fondata come BD M\u00E9rieux) \u00E8 un'azienda francese operante nel settore medicale \u2013 microbiologia e diagnostica \u2013, e specialista mondiale della diagnostica in vitro. Nel 1897, \u2013 ex allievo di Louis Pasteur \u2013 fond\u00F2 a Lione l', un laboratorio per realizzare dei vaccini antitetanici. La bioM\u00E9rieux \u00E8 stata fondata nel 1963 da \u2013 nipote di \u2013 come BD M\u00E9rieux, ed era detenuta in parti uguali dall' e da , nel 1974 Alain M\u00E9rieux divent\u00F2 l'azionista maggioritario di BD M\u00E9rieux e la societ\u00E0 prese il nome di Bio M\u00E9rieux e poi di bioM\u00E9rieux nel 1999; nel 2004 essa \u00E8 stata quotata alla borsa di Parigi. La bioM\u00E9rieux \u00E8 presente in pi\u00F9 di 160 paesi nel mondo, attraverso 43 filiali, 18 siti industriali e 17 centri di ricerca."@it . . . . . . "bioM\u00E9rieux \u00E9 uma empresa francesa especializada em diagn\u00F3sticos in vitro. Fundado em 1963, est\u00E1 localizado em , pr\u00F3ximo a Lyon. Presente em mais de 160 pa\u00EDses atrav\u00E9s de 44 localidades, o seu volume de neg\u00F3cios em 2020 ascendeu a 3.100 milh\u00F5es de euros, dos quais mais de 93% foram gerados a n\u00EDvel internacional. A empresa oferece servi\u00E7os de diagn\u00F3stico (sistemas, reagentes, software, servi\u00E7os) que determinam a origem de uma doen\u00E7a ou contamina\u00E7\u00E3o. Seus produtos s\u00E3o utilizados principalmente no diagn\u00F3stico de doen\u00E7as infecciosas. Eles tamb\u00E9m s\u00E3o usados \u200B\u200Bpara a detec\u00E7\u00E3o de microrganismos em produtos aliment\u00EDcios, farmac\u00EAuticos e cosm\u00E9ticos."@pt . "bioM\u00E9rieux SA"@en . . "bioM\u00E9rieux SA"@en . . . . "1106255701"^^ . . . . . . . . . . "bioM\u00E9rieux SA is a French multinational biotechnology company founded and headquartered in Marcy-l'\u00C9toile, France, close to Lyon. bioM\u00E9rieux is present in 44 countries and serves more than 160 countries through a large network of distributors."@en . . . . "bioM\u00E9rieux (Euronext: BIM) es una empresa francesa especializada en diagn\u00F3stico in vitro. Fundada en 1963, se encuentra en Marcy-l'\u00C9toile, cerca de Lyon. Presente en m\u00E1s de 160 pa\u00EDses a trav\u00E9s de 44 emplazamientos, su facturaci\u00F3n en 2020 ascendi\u00F3 a 3.100 millones de euros, m\u00E1s del 93% de los cuales se gener\u00F3 a nivel internacional.\u200B"@es . "bioM\u00E9rieux adalah perusahaan Prancis yang berspesialisasi dalam diagnostik in vitro. Didirikan pada tahun 1963, terletak di Marcy-l'\u00C9toile, dekat Lyon. Hadir di lebih dari 160 negara melalui 44 lokasi, omsetnya pada tahun 2020 mencapai 3.100 juta euro, lebih dari 93% di antaranya dihasilkan secara internasional. Perusahaan menawarkan layanan diagnostik (sistem, reagen, perangkat lunak, layanan) yang menentukan asal penyakit atau kontaminasi. Produknya terutama digunakan dalam diagnosis penyakit menular. Mereka juga digunakan untuk mendeteksi mikroorganisme dalam makanan, produk farmasi dan kosmetik."@in . . . . "12800"^^ . "3.1E9"^^ . "\u751F\u7269\u6885\u91CC\u57C3"@zh . . . . . "\u30D3\u30AA\u30E1\u30EA\u30E5\u30FC"@ja . "\u751F\u7269\u6885\u91CC\u57C3\uFF08\u6CD5\u8A9E\uFF1AbioM\u00E9rieux\uFF09\u662F\u4E00\u5BB6\u6CD5\u570B\u7684\u751F\u7269\u6280\u672F\u8DE8\u570B\u516C\u53F8\uFF0C\u8A72\u516C\u53F8\u5171\u670942\u4E2A\u5B50\u516C\u53F8\uFF0C\u696D\u52D9\u904D\u53CA\u5168\u7403150\u591A\u4E2A\u56FD\u5BB6\u548C\u5730\u3002"@zh . . . . . "bioM\u00E9rieux ist ein b\u00F6rsennotiertes franz\u00F6sisches Unternehmen. Es stellt Reagenzien, Ger\u00E4te, Software und Service f\u00FCr die In-vitro-Diagnostik her. bioM\u00E9rieux geh\u00F6rt mehrheitlich dem 1987 gegr\u00FCndeten ."@de . . . . . . . . . . . . . . . "Dr Marcel M\u00E9rieux"@en . . . "BioM\u00E9rieux"@in . . . . . . "BioM\u00E9rieux"@de . . . . . . . "bioM\u00E9rieux adalah perusahaan Prancis yang berspesialisasi dalam diagnostik in vitro. Didirikan pada tahun 1963, terletak di Marcy-l'\u00C9toile, dekat Lyon. Hadir di lebih dari 160 negara melalui 44 lokasi, omsetnya pada tahun 2020 mencapai 3.100 juta euro, lebih dari 93% di antaranya dihasilkan secara internasional."@in . . . . . . . "bioM\u00E9rieux SA is a French multinational biotechnology company founded and headquartered in Marcy-l'\u00C9toile, France, close to Lyon. bioM\u00E9rieux is present in 44 countries and serves more than 160 countries through a large network of distributors. bioM\u00E9rieux provides diagnostic solutions (reagents, instruments, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases, cancer screening, and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioM\u00E9rieux is listed on the NYSE Euronext Paris stock exchange (BIM \u2013 ISIN: FR0013280286)."@en . . . . . . . . . . . "5847987"^^ . . "Worldwide"@en . . . . . "Dr Alain M\u00E9rieux"@en . "3.1E9"^^ . "12628"^^ . . "BioM\u00E9rieux logo.svg"@en . . .